Theme

Tumor-type
specific Sessions

Session Title

Presentation
No.

Abstract
No.

MEDB-IS-01

SPKR-05

MEDB-O-02

MBRS-24

MEDB-O-03

MBRS-59

MEDB-O-04

MBRS-12

Lecture title

SpeakerMedulloblastomics 2020: biological and clinical insights from 1,000s of patients
Paul Northcott
Functional characterization of IKBKAP/ELP1 as a novel SHH medulloblastoma predisposition
Jesus Garcia Lopez
geneSingle-cell whole-genome sequencing dissects intra-tumoural genomic heterogeneity andMarina Danilenko
clonal evolution in childhood medulloblastoma
A transposon mutagenesis screen identifies Rreb1 as a driver for Group 3 medulloblastoma

Robert Wechsler-ReyaCountryUSAUSAUKUSAMEDB-O-05

MBRS-26

MEDB-O-06

MBRS-72

MEDB-O-07

MBRS-73

MEDB-P-08

MBRS-03

MEDB-P-09

MBRS-60

MEDB-P-10

MBRS-16

MEDB-P-11

MBRS-20

MEDB-P-12

MBRS-38

MEDB-P-13

MBRS-46

MEDB-P-14

MBRS-54

MEDB-P-15

MBRS-68

MEDB-P-16

MBRS-17

CDK7 mediated transcriptional processivity of DNA Repair networks regulates sensitivity toBethany Veo
radiation in Myc driven medulloblastoma
MiR-212 functions as a tumor suppressor gene in group 3 medulloblastoma via targeting
Sidharth Mahapatra
nuclear factor I/B (NFIB)
An exploratory analysis looking at the association of germline coding mutations with impaired
development and adaptive behavior function in pediatric medulloblastoma patients treated on Jessica Fleming
Head Start 4
Single nucleus transcriptome profiles from human developing cerebellum reveal potential
Konstantin Okonechnikov
cellular origins of medulloblastoma brain tumors
The actionable genomic landscape of relapsed medulloblastoma is defined by maintenance
Stacey Richardsonand acquisition of driver eventsMYC regulated long noncoding RNA lnc-HLX-2-7 is a putative molecular marker and aRanjan Perera
therapeutic target for Group 3 medulloblastomas in children
CSF-derived circulating tumor DNA as a biomarker for disease progression and tumor
Anthony Pak-Yin Liu
evolution in medulloblastoma
Yonehiro Kanemura
Molecular classification and clinical characteristics of 236 medulloblastomas in Japan
Charting neoplastic and immune cell heterogeneity in human and GEM models ofAndrew Donson
medulloblastoma using scRNAseq
Poor survival in replication repair deficient hypermutant medulloblastoma and CNS embryonal
Anirban Das
tumors: A Report from the International RRD Consortium
Single nucleus RNA-sequencing deciphers intratumoral heterogeneity in medulloblastoma
Kristian Pajtler
with extensive nodularity (MBEN)
Sarah Injac
Examining the role of LHX9 in group 3 medulloblastoma

MEDB-P-17

MBRS-48

Identification of novel therapeutic approaches for MYC-driven medulloblastoma

Kübra Taban

Germany

MEDB-P-18

MBRS-53

Control of medulloblastoma vasculature by a regulator of neurogenesis

Shavali Shaik

USA

MEDB-P-19

MBRS-67

Krishna Madhavan

USA

MEDB-P-20

MBRS-56

Hyeon Jin Park

Korea

MEDB-P-21

MBRS-66

Sidnei Epelman

Brazil

MEDB-P-22

MBRS-19

Till MildeGermany

MEDB-P-23

MBRS-33

Alaide Morcavallo

UK

MEDB-P-25

MBRS-47

Julien Masliah-Planchon

France

MEDB-P-26

MBRS-70

Role of cyclin dependent kinase-9 in Myc-enhanced medulloblastoma
Re-evaluation of leptomeningeal metastasis in medulloblastoma with magnetic resonanceimaging, related symptoms and cerebrospinal fluid metabolomic profiles
Cost-effective method to incorporate molecular classification of medulloblastoma into a LatinAmerican clinical trial
Synergism of HDAC and PARP inhibitors in MYC-driven Group 3 medulloblastoma cells
Temporary restoration of p53 activity during fractionated radiotherapy in a Group3Medulloblastoma GEMM represents a powerful tool for radiobiology studies
Rapid molecular subgrouping of medulloblastoma based on DNA methylation by nanopore
sequencing
Functional dependency between REST and DNMT1 in medulloblastoma

Shinji Maegawa

USAMEDB-P-27

MBRS-04

Medulloblastoma detection by blood test

Ruty Mehrian-ShaiIsrael

Miao Zhao

SwedenSidharth Mahapatra

USAYohei MineharuJapanLouisa Taylor

UK

MEDB-P-28

MBRS-10

Medulloblastoma MEDB-P-29(basic)
MEDB-P-30

MBRS-13
MBRS-22

Quiescent SOX9-positive cells behind MYC driven medulloblastoma recurrence
MiR-1253 Potentiates Cisplatin Response in Pediatric Medulloblastoma by regulating
ferroptosis
Significance of RNF213 in tumorgenicity of medulloblastoma

MEDB-P-31

MBRS-42

YB-1 - a novel therapeutic target in high-risk medulloblastoma?

MEDB-P-32

MBRS-45

MEDB-P-33

MBRS-57

MEDB-P-34

MBRS-63

MEDB-P-35

MBRS-69

MEDB-P-36

MBRS-71MEDB-P-37

MBRS-27

MEDB-P-38

MBRS-43

MEDB-P-39

MBRS-62

MEDB-P-40

MBRS-64

Alice Cardall
TWIST1 and ABCB1 are functional determinants of metastasis in medulloblastoma
Identification of MYC-dependent therapeutic vulnerabilities for targeting Group 3Gemma Llargués-Sistac
medulloblastoma
Baoli Hu
The role of the SWI/SNF complex subunit SMARCD3 in medulloblastoma
Metabolite profiling of SHH medulloblastoma identifies a subset of childhood tumours
Christopher Bennett
enriched for high-risk molecular biomarkers and clinical features
Ataxia telangiectasia and Rad3-related protein attenuates DNA damage and is a therapeutic
Krishna Madhavan
target in Myc-driven medulloblastoma
Hannah Jackson
Exosomes carry distinct miRNAs that drive medulloblastoma progression
Elucidating how novel extracellular matrix subtypes differentially impact the survival ofJames Johnson
medulloblastoma subgroups
Curaxin CBL0137 inhibits the viability of cancerous cells in pre-clinic models of MYC-amplified
Jie Mamedulloblastoma
Donghang Cheng
Study of arginine methyl transferases in medulloblastoma

USAUSAUSAGermanyUKUSAUSAJapanUSACanadaGermany
USAUKUKUSAUKUSAUKUK
China
USA

MEDB-P-41

MBRS-01

Dissecting regulators of the aberrant post-transcriptional landscape in MYC-amplified Group 3
Michelle Kameda-Smith
medulloblastoma

MEDB-P-42

MBRS-18

Tumor suppressor p53 defines the therapeutic responses in treatment of medulloblastoma

Meena Jhanwar-Uniyal

USA

MEDB-P-43

MBRS-37

Recurrent activating mutations of AKT genes in WNT-activated medulloblastomas

Julien Masliah-Planchon

France

MEDB-P-44

MBRS-39

Martin Baumgartner

Switzerland

MEDB-P-45

MBRS-51

Patricia Benites Goncalves da Sliva

GermanyMEDB-P-46

MBRS-08

Abigail Cleveland

USAMEDB-P-47

MBRS-14

Kuo-Sheng WuTaiwan

MEDB-P-48

MBRS-23

MAP4K4 controls pro-invasive signaling in medulloblastoma cells
Mutations in BRPF1 found in SHH Medulloblastoma prevent interaction with TP53 and leads
to radioresistance in vitro
Sonic Hedgehog signaling primes cerebellar granule neuron progenitors, the cell of origin for
medulloblastoma, for apoptosis by inducing pro apoptotic BIM
Integrating clinical and genomic characteristics in pediatric medulloblastoma subtypes in asingle cohort in TaiwanSignificance of mi-R33 in generation and progression of medulloblastoma

Yasuzumi Matsui

Japan

MEDB-P-49

MBRS-28

Exosomes drive medulloblastoma metastasis in a MMP2 and EMMPRIN dependent manner

Hannah Jackson

UK

MEDB-P-50

MBRS-65FBXW7 acts a tumor suppressor in MYC-driven medulloblastoma by controlling a feedforward regulatory loop of PLK1 and MYC

Dong Wang

USA

MEDB-P-51

MBRS-02

BET bromodomain protein-kinase inhibitor combinations for the treatment of medulloblastoma Nagi Ayad

USA

MEDB-P-52

MBRS-32Japan

MEDB-P-53

MBRS-61

IndiaMEDB-P-54

MBRS-29

Hiroaki Miyahara
Topoisomerase II β induces neuronal, but not glial, differentiation in medulloblastoma
Molecular sub-grouping of pediatric medulloblastoma: Correlation with clinical and histological
Gauri Deshpandefeatures, a single institutional study
Prospective molecular profiling In pediatric medulloblastoma patients enrolled on the "HeadJessica Fleming
Start 4" protocol

MEDB-P-55

MBRS-31

Combining irradiation and anti-CD47 to enhance the treatment of group 3 medulloblastoma

Osama YoussefUSA

MEDB-P-56

MBRS-06

Manabu Natsumeda

JapanMEDB-P-57

MBRS-21

Gli3 induces neuronal differentiation in WNT- and SHH- activated medulloblastoma
Clinical aggressiveness of TP53-wild type Sonic Hedgehog medulloblastoma with MYCN
amplification

Yuichi MitaniJapanCanadaUSA